Treatment of Obesity
The invention consists in a method of inducing lipid oxidation or increasing insulin sensitivity through the administration of a ligand which binds to the IL-6 receptor and signals via a gp130/LIF (leukemia inhibitory factor) receptor heterodimer. The chimeric ligand has the potential to be a highly effective therapy for obesity. Through this new methodology for increasing lipid oxidation there is no induction of an inflammatory state, no high concentrations of cytokine need to be used and no autoantibodies will be generated. The invention is particularly useful in treating subjects suffering from symptoms caused by obesity, excessive appetite and overweight, as well as obesity-associated metabolic disorders such as hypertension, osteoarthritis, type II diabetes, increased blood pressure, stroke and heart disease.
Further Information: PDF
Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937
Contact
Dr. Alexandra Baumgartner
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Bringing bio-inspired robots to life
Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…
Bella moths use poison to attract mates
Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…
AI tool creates ‘synthetic’ images of cells
…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…
